A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Neuroendocrine tumors are rare but recent data showed a relevant increase in its incidence.
The Mammalian Target of Rapamycin (mTOR), one of most important area of research, has
demonstrated be a therapeutic target in these tumors. The metformin has demonstrate in
preclinical studies having an antineoplastic action by inhibiting the mTOR pathway, and may
be an alternative treatment for this disease.
Eligible patients for this study should have metastatic gastroenteropancreatic neuroendocrine
tumors well differentiated (grade 1 or grade 2) and will be treated with metformin 850 mg
every 12 hours, and each cycle will consist of 30 days. After 180 days of treatment the
efficacy of metformin under the control of disease progression will be evaluated. As a
secondary outcome the investigator will check the patient adherence to the treatment, the
control of patient symptoms with functioning neuroendocrine tumor, and disease free survival.
Also will be performed an analysis of immunohistochemical expression of mTOR pathway proteins
of these patients.